Altria vs. Philip Morris: Which Tobacco Giant Looks Stronger?

Altria Group, Inc. MO and Philip Morris International Inc. PM are two of the most prominent names in the tobacco industry, a mature but highly profitable sector undergoing a major shift as cigarette consumption declines and consumers increasingly adopt smoke-free nicotine products. Altria is primarily focused on the U.S. market, with businesses spanning cigarettes, cigars, oral tobacco, nicotine pouches and e-vapor products.

Philip Morris, meanwhile, has a broad global footprint and sells both traditional cigarettes and smoke-free products, including heated tobacco, nicotine pouches and e-vapor offerings. Smoke-free products now account for a substantial share of PM’s revenues, highlighting how aggressively it is transforming the business. For investors, this face-off centers on which tobacco giant is better positioned to balance resilient legacy cash flows with growth in next-generation nicotine products.

Let's discuss in detail.

The Case for Altria Stock

Altria’s market position remains anchored by scale in U.S. nicotine, led by Marlboro and a broad smokeable portfolio. Its cigarette brands held 45.5% retail share in the second quarter of 2026, while Marlboro commanded 59.6% of the premium segment. Smokeable adjusted OCI reached $3 billion, with a 64.8% margin, and remained a key contributor to first-half earnings for the company.

The company is using a total-portfolio revenue growth management strategy to defend profitability across adult nicotine consumer segments. Marlboro remains the premium anchor, Cowboy Cut targets value-sensitive premium smokers and Basic addresses discount demand without accelerating growth in the discount category. The approach relies on data analytics and targeted promotions, including support in roughly 35,000 stores, to balance share retention with brand economics.

Altria is also expanding the smoke-free portfolio through Helix and on!, while its Oral Tobacco Products segment held 29% retail share in the second quarter. on! PLUS reached about 120,000 stores and supported sequential share gains, backed by premium retail visibility, live events, paid social media and trial programs. Innovation spans higher strengths, new flavors and NICOSILK soft-pouch technology.

However, challenges remain concentrated in category decline, consumer pressure and regulatory execution. Domestic cigarette volumes fell 3.2% in the second quarter, while Marlboro’s total-category share declined as discount demand increased. Oral tobacco volumes also weakened, while illicit e-vapor products remained prevalent. Management continues to emphasize pricing, targeted portfolio investments, smoke-free innovation and enforcement against illicit products.

The Case for Philip Morris Stock

Philip Morris combines global cigarette scale with a rapidly expanding smoke-free franchise. In the second quarter of 2026, its international cigarette category share held at 25.3%, while Marlboro matched a record 11% share. Smoke-free products represented about 42% of quarterly net revenues, highlighting the growing contribution of next-generation products alongside its established combustible tobacco business worldwide.

The company’s strategy centers on a multicategory smoke-free platform led by IQOS, ZYN and VEEV. Smoke-free products were available in 109 markets, while international smoke-free revenues rose 11.8% organically. Growth was supported by IQOS, expanding VEEV adoption and broader ZYN availability, giving PM multiple formats to address evolving preferences among key legal-age nicotine consumers across geographies.

Brand positioning is increasingly supported by portfolio segmentation and product innovation. ZYN held roughly 57% U.S. nicotine-pouch retail value share, while ZYN ULTRA and additional planned strength variants are broadening its ability to address consumer preferences. VEEV became Europe’s leading closed-pod brand and IQOS continued expanding through tiered consumables, new devices and technology-led offerings that deepen engagement with legal-age adult users.

However, challenges remain across regulation, category transitions and uneven regional performance. U.S. net revenues declined 0.7% year over year in the quarter, while ZYN faced competitive gaps in higher-strength and flavor segments. Flavor bans disrupted IQOS growth in parts of Europe, Japan faced excise-driven volatility and PM continues balancing investment requirements with shifting cigarette demand and regulatory uncertainty.

MO vs. PM: How Do Estimates Stack Up?

The Zacks Consensus Estimate for Altria’s 2026 and 2027 EPS has moved down 3 cents over the past 30 days to $5.67 and $5.84, respectively. The consensus estimate for MO’s 2026 and 2027 EPS indicates a year-over-year increase of around 4.6% and 3%, respectively.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Philip Morris’ 2026 and 2027 EPS has remained unchanged in the past 30 days to $8.33 and $9.16, respectively. The consensus mark for PM for 2026 and 2027 EPS implies year-over-year growth of 10.5% and 10%, respectively.

Image Source: Zacks Investment Research

MO & PM: A Look at Past-Year Stock Performance

Over the past year, Altria’s shares have climbed 4.1%, trailing both Philip Morris and the industry, which gained 18.2% and 9.7%, respectively, over the same period.

Image Source: Zacks Investment Research

MO vs. PM: A Peek Into Stock Valuation

Altria is trading at a forward 12-month price-to-earnings (P/E) ratio of 11.95, above its one-year median of 11.78. In comparison, Philip Morris trades at a forward P/E of 21.87, also above its one-year median of 20.00.

Image Source: Zacks Investment Research

MO vs. PM: Which Stock Looks More Promising Now?

Among the two tobacco giants, Philip Morris appears better placed for growth, supported by its global scale, expanding smoke-free portfolio and stronger earnings outlook. Its leadership across IQOS, ZYN and VEEV also provides broader exposure to evolving nicotine preferences. Altria remains supported by Marlboro’s U.S. strength, pricing power and disciplined portfolio management. For investors prioritizing long-term growth and industry transformation, PM appears better positioned, while Altria remains a compelling choice for stability and income.

Both MO and PM currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research